FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 240 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,333 | -50.2% | 6,289 | +137.0% | 0.00% | – |
| Q4 2022 | $26,779 | -46.4% | 2,654 | +18.7% | 0.00% | – |
| Q3 2022 | $50,000 | -82.3% | 2,235 | -80.5% | 0.00% | – |
| Q2 2022 | $283,000 | +16.9% | 11,436 | +83.4% | 0.00% | – |
| Q1 2022 | $242,000 | -48.6% | 6,236 | +14.9% | 0.00% | -100.0% |
| Q2 2021 | $471,000 | +592.6% | 5,427 | +220.9% | 0.00% | – |
| Q3 2020 | $68,000 | -71.9% | 1,691 | -76.1% | 0.00% | -100.0% |
| Q2 2020 | $242,000 | -58.6% | 7,064 | -73.2% | 0.00% | -80.0% |
| Q1 2020 | $585,000 | +1047.1% | 26,322 | +915.5% | 0.01% | – |
| Q4 2019 | $51,000 | +1175.0% | 2,592 | +881.8% | 0.00% | – |
| Q3 2019 | $4,000 | -86.7% | 264 | -82.0% | 0.00% | – |
| Q2 2019 | $30,000 | -61.0% | 1,464 | -66.5% | 0.00% | -100.0% |
| Q1 2019 | $77,000 | -22.2% | 4,364 | -43.5% | 0.00% | 0.0% |
| Q4 2018 | $99,000 | -62.5% | 7,725 | -66.9% | 0.00% | -50.0% |
| Q2 2018 | $264,000 | – | 23,312 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |